SCHEMBL13386124

SCHEMBL13386124

CCc1cc(N2C=CS(=O)(=O)C=C2)cc2c1Nc1c(CC)cc(N3CCOCC3)cc1S2

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HPGD P15428 2/20 0.39
ALDH1A1 P00352 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PIK3C2B O00750 3/20 0.32
GAA P10253 1/20 0.32
NPC1 O15118 1/20 0.31
PKM P14618 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
METAP2 P50579 1/20 0.30
NR1H4 Q96RI1 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13386254 0.84 MAPT (0.41) MAPTKDM4EMEN1KMT2AHPGD
SCHEMBL13386162 0.84 MAPT (0.44) MAPTKDM4EMEN1KMT2AHPGD
Iodide SCHEMBL13386326 0.83 MAPT (0.44) MAPTKDM4EMEN1KMT2AHPGD
SCHEMBL13737166 0.82 MEN1 (0.43) MAPTKDM4EMEN1KMT2AHPGD
SCHEMBL13386157 0.80 ALDH1A1 (0.38) MAPTKDM4EMEN1KMT2AHPGD
SCHEMBL13386320 0.78 LMNA (0.40) MAPTKDM4EMEN1KMT2AHPGD
SCHEMBL13386113 0.77 MAPT (0.44) MAPTKDM4EMEN1KMT2AHPGD
SCHEMBL2594059 0.77 MEN1 (0.39) MAPTKDM4EMEN1KMT2AHPGD
SCHEMBL16004652 0.77 LGMN (0.38) MAPTKDM4EMEN1KMT2AHPGD
SCHEMBL16004713 0.76 MAPT (0.39) MAPTKDM4EMEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8828986-B2 Antiviral compounds PROSETTA ANTIVIRAL INC. (US) 2014-09-09 US claimed
EP-2699241-B1 ANTIVIRAL COMPOUNDS PROSETTA ANTIVIRAL INC (US) 2016-07-27 EP disclosed
US-8828986-B2 Antiviral compounds PROSETTA ANTIVIRAL INC. (US) 2014-09-09 US disclosed
EP-2699241-A1 ANTIVIRAL COMPOUNDS Prosetta Antiviral Inc. (US) 2014-02-26 EP disclosed
WO-2012145567-A1 ANTIVIRAL COMPOUNDS PROSETTA ANTIVIRAL INC. (US) 2012-10-26 WO disclosed
US-20120270854-A1 Antiviral Compounds PROSETTA ANTIVIRAL INC. (US) 2012-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270854-A1 Antiviral Compounds HAVCR2, MAVS, EIF2AK2 MAPT 1569/4885KDM4E 562/4885MEN1 4541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.